TABLE 1.
Clinical characteristics of patients with Pseudomonas aeruginosa bloodstream infection compared by treatment groups
| Characteristicsa | Total n = 132 (%)b | Cases n = 44 (% or IQR)b | Controls n = 88 (% or IQR)b | P value |
|---|---|---|---|---|
| Gender (male) | 85 (64.49) | 28 (63.6) | 57 (64.8) | 1.00 |
| Age (yrs, median, IQR) | 54 (41–65) | 52 (37.2–61.7) | 54.5 (41–67.5) | 0.68 |
| Comorbidities | 47 (35.6) | 15 (34.1) | 32 (36.4) | 0.84 |
| Chronic cardiac disease | 18 (13.6) | 3 (6.8) | 15 (17) | 0.17 |
| Diabetes mellitus | 11 (8.3) | 3 (6.8) | 8 (9.1) | 0.75 |
| Chronic obstructive pulmonary disease | 10 (7.6) | 1 (2.3) | 9 (10.2) | 0.16 |
| Chronic liver disease | 7 (5.3) | 2 (4.5) | 5 (5.7) | 1.00 |
| Chronic kidney disease | 4 (3) | 2 (4.5) | 5 (5.7) | 0.60 |
| Hematologic malignancy | ||||
| Acute myeloid leukemia | 67 (50.8) | 24 (54.5) | 43 (48.9) | 0.58 |
| Acute lymphoid leukemia | 15 (11.4) | 6 (13.6) | 9 (10.2) | 0.57 |
| Lymphoproliferative disorder | 36 (27.3) | 10 (22.7) | 26 (29.5) | 0.53 |
| Chronic lymphocytic leukemia | 5 (3.8) | 2 (4.5) | 3 (3.4) | 1.00 |
| Multiple myeloma | 5 (3.8) | 1 (2.3) | 4 (4.5) | 0.66 |
| Other | 4 (3) | 1 (2.3) | 3 (3.4) | 1.00 |
| Hematopoietic stem cell transplant (HSCT) | 49 (37.1) | 17 (38.6) | 32 (36.4) | 0.79 |
| Type of HSCT | ||||
| Autologous HSCT | 3 (6.2) | 0 (0) | 3 (9.7) | 0.54 |
| Allogeneic HSCT | 45 (91.8) | 17 (100) | 28 (87.5) | 0.54 |
| Graft-versus-host disease | 14 (32.6) | 6 (40) | 8 (28.6) | 0.50 |
| Uncontrolled disease | 55 (45.5) | 19 (45.2) | 36 (45.6) | 0.97 |
| High-risk MASCC score (<21 points) | 90 (75.6) | 33 (75) | 57 (76) | 1.00 |
| Profound neutropenia (<0.1 × 109) | 84 (64.1) | 31 (70.5) | 53 (60.9) | 0.340 |
| Duration of neutropenia prior to infection (days, median, IQR) | 7 (2–15) | 8 (2–16) | 7 (3–15) | 0.910 |
| Duration of neutropenia after infection (days, median, IQR) | 5 (2–12) | 8 (4–19) | 4 (2–9) | 0.080 |
| Prior fluoroquinolone prophylaxis (1 mo) | 53 (40.2) | 25 (56.8) | 28 (31.8) | 0.006 |
| Prior antibiotic therapy (1 mo) | 106 (80.9) | 36 (81.8) | 79 (80.5) | 1.000 |
| Previous corticosteroid therapy (1 mo) | 78 (60) | 23 (52.3) | 55 (64) | 0.256 |
| Prior hospital admission (3 mo) | 84 (64.1) | 31 (70.5) | 53 (60.9) | 0.337 |
| Prior ICU admission (3 mo) | 19 (14.4) | 9 (20.5) | 10 (11.4) | 0.192 |
| Nosocomial acquisition | 126 (95.5) | 44 (100) | 82 (93.2) | 0.18 |
| Source of BSI | ||||
| Endogenous source | 47 (35.6) | 13 (29.5) | 34 (38.6) | 0.40 |
| Pneumonia | 34 (25.8) | 9 (20.5) | 25 (28.4) | 0.401 |
| Intravascular catheter infection | 14 (10.6) | 3 (6.8) | 11 (12.5) | 0.384 |
| Skin and soft tissue infection | 9 (6.8) | 5 (11.4) | 4 (4.5) | 0.15 |
| Urinary tract infection | 8 (6.1) | 5 (11.4) | 3 (3.4) | 0.116 |
| Perianal infection | 7 (5.3) | 3 (6.8) | 4 (4.5) | 0.686 |
| Mucositis | 4 (3) | 1 (2.3) | 3 (3.4) | 1.000 |
| Neutropenic enterocolitis | 4 (3) | 1 (2.3) | 3 (3.4) | 1.000 |
| Other | 6 (4.5) | 4 (9.1) | 2 (2.3) | 0.09 |
| High-risk BSI | 68 (51.5) | 25 (56.8) | 43 (48.9) | 0.461 |
| Polymicrobial BSI | 6 (4.6) | 2 (4.5) | 4 (4.5) | 1.000 |
| Septic shock at presentation | 42 (32.1) | 13 (29.5) | 29 (33.3) | 0.697 |
| Gangrenous ecthyma | 10 (7.6) | 8 (18.2) | 2 (2.3) | 0.002 |
| Multidrug-resistant Pseudomonas aeruginosa | 120 (90.9) | 40 (90.9) | 80 (90.9) | 1.000 |
| Extensively resistant P. aeruginosa | 44 (33.3) | 15 (34.1) | 29 (33) | 0.89 |
a
BSI, bloodstream infection; MASCC, Multinational Association for Supportive Care in Cancer.
b
Qualitative data are expressed as numbers (%), unless otherwise indicated, and quantitative data are expressed as means ± standard deviation (SD) or median and interquartile range (IQR; 25th to 75th percentiles), as appropriate.